FGFR1与EGFR在肺癌发生中协同作用,联合抑制可提高疗效
在肺腺癌及永生化肺细胞系中进行FGFR1与EGFR过表达及共过表达实验,并行体外和体内(细胞系及患者来源异种移植)单药与联合EGFR/FGFR抑制剂敏感性实验,另在抗EGFR治疗肺腺癌队列中检测FGFR1 mRNA。结果显示FGFR1与EGFR协同增强EGFR活化及致癌信号,高FGFR1表达预测对厄洛替尼或吉非替尼耐药,双抑制在过表达模型中具协同效应。
要点
- FGFR1与EGFR在肺腺癌中协同增强EGFR活化及致癌信号。
- 高FGFR1表达预测EGFR突变及野生型肺腺癌对厄洛替尼或吉非替尼耐药。
- 在FGFR1过表达且EGFR活化的模型中,双抑制对肿瘤生长具协同效应。
核心结论
- 结果支持在EGFR突变肺腺癌中,对FGFR1过表达且EGFR活化的选定患者,将EGFR抑制剂与FGFR抑制剂联合使用以扩展EGFR抑制剂单药之外的用途。
研究设计与样本
- 在腺癌及永生化肺细胞系中进行FGFR1与EGFR过表达和共过表达实验,并开展替代与相互作用实验。
- 在体外及细胞系来源和患者来源异种移植中,进行单药和联合EGFR/FGFR抑制剂敏感性实验。
- 在抗EGFR治疗肺腺癌患者队列中检测FGFR1 mRNA表达。
主要发现
- 报告FGFR1与EGFR在该背景下协同相互作用,导致EGFR活化及致癌信号增强。
- 体外和体内证据表明,在EGFR突变和EGFR野生型模型中,FGFR1表达增加高EGFR活化细胞的致瘤性。
- 临床层面,在酪氨酸激酶抑制剂治疗的EGFR突变和EGFR野生型肺腺癌患者队列中,高FGFR1表达水平预测对厄洛替尼或吉非替尼更高的耐药性。
- 在FGFR1过表达、EGFR活化的模型中,双抑制EGFR和FGFR在体外及细胞系来源和患者来源异种移植中对肿瘤生长显示协同效应。
临床怎么用
- 作者认为,具有FGFR1过表达和EGFR活化特征的肿瘤患者可能从联合EGFR/FGFR抑制中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma. METHODS: We performed FGFR1 and EGFR overexpression and co-overexpression assays in adenocarcinoma and in inmortalized lung cell lines, and we also carried out surrogate and interaction assays. We performed monotherapy and combination EGFR/FGFR inhibitor sensitivity assays in vitro and in vivo in cell line- and patient-derived xenografts. We determined FGFR1 mRNA expression in a cohort of patients with anti-EGFR therapy-treated adenocarcinoma. RESULTS: We have reported a cooperative interaction between FGFR1 and EGFR in this context, resulting in increased EGFR activation and oncogenic signaling. We have provided in vitro and in vivo evidence indicating that FGFR1 expression increases tumorigenicity in cells with high EGFR activation in EGFR-mutated and EGFR wild-type models. At the clinical level, we have shown that high FGFR1 expression levels predict higher resistance to erlotinib or gefitinib in a cohort of patients with tyrosine kinase inhibitor-treated EGFR-mutated and EGFR wild-type lung adenocarcinoma. Dual EGFR and FGFR inhibition in FGFR1-overexpressing, EGFR-activated models shows synergistic effects on tumor growth in vitro and in cell line- and patient-derived xenografts, suggesting that patients with tumors bearing these characteristics may benefit from combined EGFR/FGFR inhibition. CONCLUSION: These results support the extended the use of EGFR inhibitors beyond monotherapy in the EGFR-mutated adenocarcinoma setting in combination with FGFR inhibitors for selected patients with increased FGFR1 overexpression and EGFR activation.
引用
- Quintanal-Villalonga A, Molina-Pinelo S, Cirauqui C, et al. FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. J Thorac Oncol. 2019. PMID: 30639621. doi:10.1016/j.jtho.2018.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。